advanced search

RESPIRATORY

SUSTAINABILITY
REINVENTING THE pMDI: EVOLVING A PROVEN PLATFORM FOR A LOW-GWP FUTURE
Chris Baron discusses how lower-global warming potential pressurised metered dose inhalers are moving from development to commercialisation and explains why manufacturing readiness and supply resilience are critical, going on to introduce Aptar Pharma’s ZEN30 Futurity®, designed to anticipate current and emerging regulatory expectations.
EXPERT VIEW
ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS
Markus Laubscher discusses the role of pressurised metered dose inhalers in the context of healthcare’s drive towards sustainability, considering the need for lower-global-warming-potential propellants and why it is important to preserve these inhalers as a key aspect of respiratory care.
INDUSTRIALISING DRUG DELIVERY DEVICES: INSIGHTS FROM 40 YEARS OF GETTING TO MARKET
EXPERT VIEW
Chris Hurlstone
INDUSTRIALISING DRUG DELIVERY DEVICES: INSIGHTS FROM 40 YEARS OF GETTING TO MARKET
Chris Hurlstone looks at the process of developing drug delivery systems through the industrialisation phase and explores ways to address the challenges that arise along the way. Drawing on Team’s 40-year track record of supporting drug delivery device innovation, the insights are intended for teams involved in developing drug delivery systems, particularly those responsible for design, engineering, industrialisation and manufacturing transfer.
HOW MODERN PROTOTYPING ACCELERATES DRUG DELIVERY DEVICE DEVELOPMENT
INDUSTRIALISATION
Erwin van Huijksloot
IGS GeboJagema
HOW MODERN PROTOTYPING ACCELERATES DRUG DELIVERY DEVICE DEVELOPMENT
Erwin van Huijksloot and Joe Melton discuss the importance of early prototyping, ensuring a strong understanding of production efficiency and possible variability is grasped before large-scale manufacture begins.
CLOSING THE SAFETY GAP: WHY PHARMA-DEDICATED LABELS MATTER
INDUSTRIALISATION
Paavo Sillanpää
UPM Adhesive Materials
CLOSING THE SAFETY GAP: WHY PHARMA-DEDICATED LABELS MATTER
Paavo Sillanpää discusses why pharma-dedicated labels matter for more challenging labelling applications as well as how to avoid potential label failure and brand risk.
CHALLENGES & OPPORTUNITIES TO OPTIMISE SUSTAINABILITY IN PHARMACEUTICAL PACKAGING & COMBINATION DEVICES
EXPERT VIEW
Greg Anderson
CHALLENGES & OPPORTUNITIES TO OPTIMISE SUSTAINABILITY IN PHARMACEUTICAL PACKAGING & COMBINATION DEVICES
Greg Anderson discusses the need to improve the sustainability and circularity of pharmaceutical packaging and drug delivery devices, looking at the challenges and providing a clear outline of the potential opportunities for improvement.
THE PHYSICS OF THE SWITCH: OPTIMISING pMDI DESIGN FOR LOW-CARBON LUNG DELIVERY
SUSTAINABILITY
Thomas Daly
Bespak
THE PHYSICS OF THE SWITCH: OPTIMISING pMDI DESIGN FOR LOW-CARBON LUNG DELIVERY
Thomas Daly and Tony Mallett discuss the transition to low-global warming potential propellants, examining the vital adjustments to the whole inhalation system necessary to support effective and safe dosing without hydrofluorocarbons.
EXPANDING HORIZONS IN LIQUID NASAL DRUG DEVELOPMENT
NASAL
Dr Alan Watts
Catalent Pharma Solutions
EXPANDING HORIZONS IN LIQUID NASAL DRUG DEVELOPMENT
Dr Alan Watts and David Wilcox examine the current product designs in the nasal market landscape and outline key technical and regulatory considerations for liquid nasal drug products.
Interview: Inside The Crux Technology Centre
INDUSTRIALISATION
Stephen Gilmore
Crux Product Design
Interview: Inside The Crux Technology Centre
Stephen Gilmore discusses the opportunities and capabilities unlocked by Crux’s new Technology Centre located in Bristol, UK. Mr Gilmore provides an overview of the new capabilities provided by the facility and the potential it represents to the future of the company.
DE-RISKING DEVICE SELECTION – WHY CHOOSE UNISPRAY FOR NALOXONE RESCUE APPLICATIONS
NASAL
Elsie Thomas
Nemera
DE-RISKING DEVICE SELECTION – WHY CHOOSE UNISPRAY FOR NALOXONE RESCUE APPLICATIONS
Elsie Thomas explains why UniSpray is a robust nasal platform for generic naloxone, based on an evidence-driven approach that combines usability studies, threshold analyses and interchangeability assessments, and how it ensures safe and reliable performance, intuitive use, and regulatory acceptability in real-world opioid overdose rescue situations.
A NOVEL HUMAN FACTORS APPROACH FOR A NEW PLATFORM-BASED, BREATH-TRIGGERED NEBULISER
PULMONARY
Simon Buchner
PARI
A NOVEL HUMAN FACTORS APPROACH FOR A NEW PLATFORM-BASED, BREATH-TRIGGERED NEBULISER
Simon Bucher, Dr Amy MacDonald and Dr John DeFoggi explain how human factors engineering is at the centre of the development of PARI’s breath-triggered eFlow® Integrated nebuliser, and consider how this approach preserves scientific rigour while avoiding redundant testing and ensuring efficient resource allocation.
REFRAMING THE ROLE OF NASAL SPRAYS IN AN INCREASINGLY PATIENT-CENTRIC DRUG DELIVERY LANDSCAPE
NASAL
Eric Kaneps
LTS
REFRAMING THE ROLE OF NASAL SPRAYS IN AN INCREASINGLY PATIENT-CENTRIC DRUG DELIVERY LANDSCAPE
Eric Kaneps looks at the reality of nasal drug delivery for liquid formulations and considers how advances not only open new opportunities but can also be seen in the context of a groundswell of momentum around non-invasive, patient-centric delivery. Mr Kaneps reflects on how this shift in dynamics, coupled with a shift in mindset, is opening the door for pharmaceutical companies to expand their drug delivery options and fully optimise the development pathway for their molecule.
HOW SOFT MIST INHALERS WILL BREATHE NEW LIFE INTO DRUG DEVELOPMENT
PULMONARY
Kasim Yilginc
GAPLAST
HOW SOFT MIST INHALERS WILL BREATHE NEW LIFE INTO DRUG DEVELOPMENT
Kasim Yilginc discusses the expanding importance and influence of the respiratory sector within pharmaceutical pipelines, including the role that soft mist inhalers are poised to play in improving patient outcomes and how GAPLAST’s AirlessMotion® bag-in-bottle technology can support the development of these inhalation devices.
ACOUSTIC WAVE PLATFORM NEBULISER FOR INHALED DELIVERY OF BIOLOGIC THERAPIES
PULMONARY
Dr Elijah Nazarzadeh
Nebu~Flow
ACOUSTIC WAVE PLATFORM NEBULISER FOR INHALED DELIVERY OF BIOLOGIC THERAPIES
Dr Elijah Nazarzadeh reports on the applications of Nebu~Flow, an acoustic wave-based nebuliser platform, addressing the challenges associated with drug delivery to the lungs via more efficient aerosolisation, enabling precise inhaled delivery of life-changing treatments.
AUTOMATING MDI ACTUATION: PRECISION DATA WITH LESS EFFORT
PULMONARY
Paul Martin
Copley Scientific
AUTOMATING MDI ACTUATION: PRECISION DATA WITH LESS EFFORT
Paul Martin considers how automation can enhance testing for metered dose inhalers by removing the variability in actuation technique introduced by manual operation, presenting two case studies that demonstrate this potential improvement in data quality.
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
EXPERT VIEW
Dr Matthew Owen
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.
MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION
NASAL
SGD Pharma
MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION
SGD Pharma discusses the advantages and benefits of the company’s recent partnership with Prince Sterilization Services, with a focus on the first product platform developed based on this collaboration – the My Sterinity Nasal platform of Type I glass primary containers for sensitive, long-term nasal therapeutics. Additionally, SGD Pharma highlights its presence at DCAT Week 2026.
THE IMPORTANCE OF MESH NEBULISER CONFIGURATION IN mRNA-LNP DELIVERY PERFORMANCE
CGT
Hanna Beike
PARI
THE IMPORTANCE OF MESH NEBULISER CONFIGURATION IN mRNA-LNP DELIVERY PERFORMANCE
Hanna Beike and Dr Benjamin Heine highlight the superior performance of customisable drug-specific nebuliser platforms, such as eFlowM® Open System and eFlow® Integrated, for the delivery of messenger RNA-based inhalation therapies.
CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT
PULMONARY
Carolyn Berg
Catalent Pharma Solutions
CHARTING THE COURSE FOR PULMONARY DRUG DEVELOPMENT
Carolyn Berg and Dr Alan Watts examine strategy considerations that can help emerging biotech companies navigate early-stage pulmonary drug development, providing practical guidance for addressing challenges of respiratory delivery and avoiding common pitfalls that can derail development programmes.
Interview: Aptar Pharma Expansion With New R&D Center
INTERVIEW
Christophe Pierre
Aptar Pharma
Interview: Aptar Pharma Expansion With New R&D Center
In this interview, Christophe Pierre introduces Aptar Pharma’s new R&D Center in France, and outlines how the new facility will assist the development of smarter, more integrated drug delivery solutions, facilitating progression from concept to full-scale industrialisation across multiple therapeutic fields.
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
EXPERT VIEW
Mark Parry
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
Mark Parry discusses the potential needs and opportunities for respiratory drug delivery devices in the context of a hypothetical global vaccination strategy, considering a variety of factors and how different respiratory device approaches could perform.
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
EXPERT VIEW
Dr Yannick Baschung
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
Dr Yannick Baschung discusses the benefits and challenges of orally inhaled and nasal drug products and examines how drug developers can stress test their products to improve regulatory success and patient safety, as well as how partnering with an expert CRO can provide an efficient way of performing critical characterisation testing.
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
EXPERT VIEW
Jamie Clayton
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
As dissolution testing rises up the agenda for orally inhaled product developers, Jamie Clayton explores drivers behind its adoption and key considerations for developing a robust and relevant method.
INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES
PULMONARY
Dr Philippe Rogueda
Merxin Ltd
INHALED OLIGONUCLEOTIDES – THE FUTURE FOR RESPIRATORY DISEASES
Dr Philippe Rogueda discusses the therapeutic potential promised by oligonucleotides and presents the case for prioritising the inhalation route as the ideal delivery mechanism for these drugs, highlighting how direct delivery to the lungs via devices such as dry power inhalers or soft mist inhalers can maximise the therapeutic efficacy and minimise the side effects of these exciting drugs.
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
EXPERT VIEW
Dr Peter Harley
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
Dr Peter Harley, Mariam Al-Amari and Matt Jones explore how in silico approaches can transform pulmonary and nasal drug delivery device development, illustrating through case studies – spanning low-global-warming potential propellants, assembly robustness, device-user interaction, variability and capsule piercing dynamics – how simulation-led in silico approaches can improve understanding of device performance and identify risks early, reducing development costs and accelerating the path to more reliable, innovative and patient-friendly drug-device systems.
DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE
EXPERT VIEW
Chris Gilmor
DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE
Chris Gilmor considers the issues affecting dry powder inhalers and explains how formulators use a range of techniques to ensure dose dispersion and API detachment. He goes on to explain the importance of controlling the moisture level in these devices and how it can affect the drug delivery performance of the formulation.
Top